STAMFORD, Conn. — August 5, 2026 — Leads & Copy — Curaleaf Holdings, Inc., a leading international provider of consumer products in the cannabis industry, today announced its financial and operating results for the second quarter ended June 30, 2026. The company reported second quarter net revenue of $340 million, an increase of 10% year-over-year, driven by growth in both domestic and international segments. Domestic revenue grew 7% and international revenue increased by 26% compared to the prior year.
Curaleaf’s U.S. business demonstrated regained momentum, marking the second consecutive quarter of domestic year-over-year growth. The company’s ‘Built for Growth’ strategy, which emphasizes customer centricity, brand building, and operational excellence, is showing positive results across the business.
For the second quarter of 2026, gross profit margin stood at 50%, with adjusted EBITDA reaching $70 million, representing a 21% margin. Net income from continuing operations was $12.5 million, and the company concluded the quarter with $107 million in cash on its balance sheet. Chairman and CEO Boris Jordan expressed confidence in the company’s strategic direction and operational discipline, stating that Curaleaf is well-positioned to lead the next phase of the cannabis industry.
Detailed financial highlights for the second quarter of 2026 include net revenue of $340.1 million, a 10% increase from the $310.6 million reported in Q2 2025. Sequentially, net revenue saw a 5% increase from Q1 2025. Gross profit was $169.9 million with a 50% gross profit margin, an increase of 70 basis points year-over-year. Net income attributable to Curaleaf Holdings, Inc. from continuing operations was $12.5 million, or $0.05 per diluted share. Adjusted EBITDA was $70.1 million with an adjusted EBITDA margin of 20.6%, a 120 basis point decrease year-over-year. Total cash and cash equivalents at the quarter’s end were $107.0 million.
Looking at the first six months of 2026, net revenue totaled $664.3 million, an 8% increase compared to $617.2 million in the same period of 2025. Gross profit reached $327.2 million with a gross margin of 49%, a decrease of 80 basis points year-over-year. Net income from continuing operations for the six-month period was $82.6 million, or $0.32 per diluted share. Adjusted EBITDA for the first six months was $133.5 million with an adjusted EBITDA margin of 20.1%, a 100 basis point decrease year-over-year. During this period, Curaleaf retired and repurchased 1.01 million shares for $7.4 million.
Operational highlights for the second quarter of 2026 include the expansion of the retail footprint in Florida to 73 locations with new dispensaries in Jacksonville Beach and Fernandina Beach, bringing the nationwide total to 174 operated and managed dispensaries. The company also launched its ultra-premium flower brand, Dark Heart, across 11 states. Curaleaf completed the buyout of its German subsidiary, Four20 Pharma, increasing its ownership of Curaleaf International to 100%. Additionally, the company applied to register all its medical cultivation, processing, and dispensing locations with the DEA and appointed Torsten Greif and Faith Charles to its Board of Directors.
Post second quarter highlights include Curaleaf Spain receiving approval for two cannabis medicines and the opening of two more dispensaries in Florida, bringing the total retail footprint to 176. The company also began offering trading in listed options on its TSX-listed CURA shares on the Montreal Exchange.
Curaleaf reports its financial results in accordance with U.S. GAAP and also uses non-GAAP financial measures such as Adjusted EBITDA to evaluate performance. These measures provide additional insight into the company’s financial strength and underlying performance.
Source: Curaleaf Holdings, Inc.
